HK1102287A1 - Antibodies against clostridium difficile toxins and uses thereof - Google Patents

Antibodies against clostridium difficile toxins and uses thereof

Info

Publication number
HK1102287A1
HK1102287A1 HK07110397.1A HK07110397A HK1102287A1 HK 1102287 A1 HK1102287 A1 HK 1102287A1 HK 07110397 A HK07110397 A HK 07110397A HK 1102287 A1 HK1102287 A1 HK 1102287A1
Authority
HK
Hong Kong
Prior art keywords
antibodies against
clostridium difficile
difficile toxins
against clostridium
toxins
Prior art date
Application number
HK07110397.1A
Other languages
English (en)
Inventor
Donna Ambrosino
Gregory J Babcock
Theresa Broering
Robert Graziano
Hector Javier Hernandez
Israel Lowy
Robert Mandell
Deborah Molrine
William D Thomas
Hui-Fen Zhang
Original Assignee
Univ Massachusetts
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1102287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Massachusetts, Medarex Inc filed Critical Univ Massachusetts
Publication of HK1102287A1 publication Critical patent/HK1102287A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/809Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
HK07110397.1A 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof HK1102287A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US61385404P 2004-09-28 2004-09-28
PCT/US2005/003725 WO2006121422A2 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Publications (1)

Publication Number Publication Date
HK1102287A1 true HK1102287A1 (en) 2007-11-09

Family

ID=36928722

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11105869.4A HK1152048A1 (en) 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof
HK07110397.1A HK1102287A1 (en) 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof
HK15109420.4A HK1208873A1 (en) 2004-02-06 2015-09-24 Antibodies against clostridium difficile toxins and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11105869.4A HK1152048A1 (en) 2004-02-06 2007-09-25 Antibodies against clostridium difficile toxins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15109420.4A HK1208873A1 (en) 2004-02-06 2015-09-24 Antibodies against clostridium difficile toxins and uses thereof

Country Status (28)

Country Link
US (8) US7625559B2 (pl)
EP (3) EP2270045B8 (pl)
JP (3) JP4588763B2 (pl)
KR (3) KR101332927B1 (pl)
CN (1) CN101014620B (pl)
AT (1) ATE512986T1 (pl)
AU (1) AU2005320349C1 (pl)
BE (1) BE2017C023I2 (pl)
BR (1) BRPI0507433C1 (pl)
CA (1) CA2553946C (pl)
CY (3) CY1111860T1 (pl)
DK (3) DK2270045T3 (pl)
ES (3) ES2366626T3 (pl)
HK (3) HK1152048A1 (pl)
HR (1) HRP20110599T1 (pl)
HU (3) HUE034552T2 (pl)
LT (2) LT2857418T (pl)
LU (1) LUC00025I2 (pl)
MX (1) MXPA06008839A (pl)
NL (1) NL300881I2 (pl)
NO (2) NO340300B1 (pl)
NZ (2) NZ548821A (pl)
PL (3) PL2270045T3 (pl)
PT (3) PT2857418T (pl)
RS (1) RS51908B (pl)
SI (3) SI2857418T1 (pl)
WO (1) WO2006121422A2 (pl)
ZA (1) ZA200606516B (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
AU2005257527B9 (en) * 2004-06-28 2009-03-05 Japan Science And Technology Agency Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and vero toxin-neutralizing agent
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CA2963138C (en) 2007-01-30 2019-05-14 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
ES2589606T3 (es) * 2009-07-27 2016-11-15 Biodics Gmbh Procedimiento para la detección y para la identificación de una cepa de C. difficile variante en una muestra
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
BR112012026021B1 (pt) 2010-04-15 2022-05-03 Progenics Pharmaceuticals, Inc Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2632949B1 (en) * 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
EP2661500A2 (en) * 2010-12-29 2013-11-13 Cangene Corporation Clostridium difficile antigens
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
AU2012321317B2 (en) * 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
EP2748194A4 (en) 2011-08-22 2015-01-28 Cangene Corp ANTIBODIES OF THE DIFFICULT CLOSTRIDIUM
SG11201400193SA (en) 2011-09-16 2014-05-29 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CN108101983A (zh) * 2012-03-02 2018-06-01 瑞泽恩制药公司 艰难梭状芽孢杆菌毒素的人源抗体
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JPWO2014061783A1 (ja) * 2012-10-19 2016-09-05 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013352034B2 (en) * 2012-11-28 2018-08-02 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
EP2986316B1 (en) * 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
US10822399B2 (en) 2014-02-10 2020-11-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
SG10201806481XA (en) 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CA3104268A1 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
WO2015184454A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Clostridium difficile culture medium
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
WO2019204784A1 (en) * 2018-04-19 2019-10-24 First Light Biosciences, Inc. Detection of targets
US20220226430A1 (en) * 2019-05-11 2022-07-21 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
CN114853896B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
EP0618970A1 (en) * 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
EP1041149B8 (en) 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (psma)에 대한 인간모노클로날 항체
JP2005526506A (ja) * 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Kdrに特異的なヒト抗体及びその利用
US7262277B2 (en) * 2002-03-21 2007-08-28 Eli Lilly And Company Antagonistic anti-hFAS ligand human antibodies and fragments thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1572736A2 (en) 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
KR20130133302A (ko) * 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ip―10 항체 및 그의 용도
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
BRPI0507433B1 (pt) 2018-03-20
BE2017C023I2 (pl) 2024-08-08
KR20070050863A (ko) 2007-05-16
US20140120614A1 (en) 2014-05-01
ES2533492T3 (es) 2015-04-10
US20100233181A1 (en) 2010-09-16
CN101014620A (zh) 2007-08-08
JP2013153750A (ja) 2013-08-15
SI2270045T1 (sl) 2015-06-30
EP2270045B1 (en) 2014-12-31
WO2006121422A8 (en) 2007-04-26
US9217029B2 (en) 2015-12-22
US8236311B2 (en) 2012-08-07
LT2857418T (lt) 2017-09-25
NZ580828A (en) 2011-09-30
US20160152694A1 (en) 2016-06-02
CA2553946A1 (en) 2005-08-06
JP5319622B2 (ja) 2013-10-16
EP1766093A2 (en) 2007-03-28
EP1766093B1 (en) 2011-06-15
SI1766093T1 (sl) 2011-12-30
MXPA06008839A (es) 2008-03-07
PL1766093T3 (pl) 2011-11-30
PL2270045T3 (pl) 2015-06-30
US20120288508A1 (en) 2012-11-15
DK2857418T3 (en) 2017-10-23
CY2017022I1 (el) 2017-11-14
JP4588763B2 (ja) 2010-12-01
LUC00025I1 (pl) 2017-07-06
DK1766093T3 (da) 2011-10-03
US20210269511A1 (en) 2021-09-02
WO2006121422A2 (en) 2006-11-16
PT1766093E (pt) 2011-08-24
LUC00025I2 (pl) 2017-09-08
EP2857418B1 (en) 2017-07-26
JP5717300B2 (ja) 2015-05-13
AU2005320349A1 (en) 2006-08-24
DK2270045T3 (en) 2015-04-07
BRPI0507433B8 (pt) 2018-04-10
EP2270045B8 (en) 2015-02-25
CY2017022I2 (el) 2017-11-14
JP2007533330A (ja) 2007-11-22
ZA200606516B (en) 2011-01-26
BRPI0507433C1 (pt) 2021-05-25
KR20120003017A (ko) 2012-01-09
PL2857418T3 (pl) 2017-10-31
ATE512986T1 (de) 2011-07-15
RS51908B (en) 2012-02-29
CN101014620B (zh) 2012-05-09
PT2857418T (pt) 2017-10-20
US20100233182A1 (en) 2010-09-16
HK1208873A1 (en) 2016-03-18
HUE034552T2 (en) 2018-02-28
NO2017032I1 (no) 2017-07-07
ES2643760T3 (es) 2017-11-24
AU2005320349B8 (en) 2010-04-22
NL300881I2 (nl) 2024-07-16
LTC2270045I2 (lt) 2019-12-10
CA2553946C (en) 2019-02-26
NO20063767L (no) 2006-10-02
CY1119416T1 (el) 2018-03-07
KR101332927B1 (ko) 2013-11-26
SI2857418T1 (en) 2018-01-31
US8609111B2 (en) 2013-12-17
WO2006121422A3 (en) 2007-03-15
AU2005320349A8 (en) 2008-08-07
HUS1700028I1 (hu) 2017-07-28
NZ548821A (en) 2009-12-24
HK1152048A1 (en) 2012-02-17
HUE024962T2 (en) 2016-02-29
EP2857418A1 (en) 2015-04-08
US8257709B2 (en) 2012-09-04
KR20120083534A (ko) 2012-07-25
NO340300B1 (no) 2017-03-27
CY1111860T1 (el) 2015-11-04
US20180208643A1 (en) 2018-07-26
BRPI0507433A (pt) 2007-07-03
EP2270045A1 (en) 2011-01-05
JP2011019516A (ja) 2011-02-03
KR101332994B1 (ko) 2013-11-26
US7625559B2 (en) 2009-12-01
AU2005320349C1 (en) 2019-06-13
LTPA2017022I1 (lt) 2017-09-11
HRP20110599T1 (hr) 2011-10-31
PT2270045E (pt) 2015-04-08
US20050287150A1 (en) 2005-12-29
AU2005320349B2 (en) 2010-04-08
ES2366626T3 (es) 2011-10-24

Similar Documents

Publication Publication Date Title
HUS1700028I1 (hu) Antitestek a Clostridium difficile toxinok ellen és azok felhasználásai
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2006119062A3 (en) Sclerostin epitopes
TW200716667A (en) Binding agents
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
WO2006053301A3 (en) Fc variants with altered binding to fcrn
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2005092925A3 (en) Immunoglobulin variants outside the fc region
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2006085938A3 (en) Il-13 binding agents
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
MX2010001237A (es) Nuevos anticuerpos.
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2006116319A3 (en) Reagents that bind ccx-ckr2
WO2007002525A3 (en) Tomoregulin antibodies and uses thereof
CY1116371T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ αυτων
WO2006136892A3 (de) Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: [71] CORRECTION OF THE NAME OF APPLICANT FROM UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER TO UNIVERSITY OF MASSACHUSETTS. UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER UNIVERSITY OF MASSACHUSETTS